Medicus Pharma Ltd.

Medicus Pharma Ltd. (MDCX), a clinical-stage biotech company, reported a net loss of $35.4M for FY 2025 ending December 31, 2025, driven by total operating expenses of $34.4M, including $17.9M in general and administrative, $7.7M in research and development, and $8.7M in in-process R&D for Teverelix. Loss from operations was $34.4M, with additional other expenses of $1.1M contributing to the net loss. Net loss attributable to common shareholders reached $47.3M after a $11.8M deemed dividend on warrant inducement, resulting in basic and diluted EPS of -$3 on 17.3M weighted average shares. Balance sheet shows $10.1M total assets, including $8.7M cash, against $10.0M liabilities, yielding minimal equity of $37K. Cash flows reflected $22.8M used in operations, $31.9M from financing, and $4.6M used in investing (Antev acquisition), netting a $4.5M cash increase to $8.7M. No revenue generated as a pre-commercial entity. Forward-looking, focus remains on Phase 2 trials for SkinJect (D-MNA for BCC) and Teverelix (GnRH antagonist), with ongoing financing via SEPA ($15M facility) and ATM ($15.3M) to fund development amid going concern risks.

Key Takeaways